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Summary
Objective The assessment of GH deficiency in adult patients
with Prader-Willi syndrome (PWS) has been previously assessed
through the evaluation of quantitative parameters, such as the
peak value of GH response to exogenous stimuli. A comprehen-
sive description of the pattern of secretory response obtainable
by deconvolution analysis is still lacking. The aim of our study
was to characterize the time evolution of responses of PWS
subjects compared with obese controls.
Design and subjects GH responsiveness was measured follow-
ing the combined administration of GHRH+arginine to 65 PWS
adults (24 males, 41 females) aged 18–412 years, and 17 age-,
gender- and body mass index-matched obese controls. PWS sub-
jects were analysed considering the stratification on different
genotypes.
Measurements GH response to GHRH+arginine was analysed
in terms of peak values, standard area under the curves (AUCs),
AUCs due to the stimulus, AUCs of the Instantaneous Secretion
Rate signal and Secretion Response Analysis.
Results In terms of both peak values and AUC, GH responses
were statistically different between PWS UPD15 and PWS
DEL15 subjects as well as between PWS UPD15 and obese
controls. PWS subjects showed a lower and a more delayed GH
response compared with obese controls. Moreover, PWS UPD15
subjects had the most delayed GH response.
Conclusions Our findings demonstrate that impaired GH
secretion in PWS subjects compared with obese controls regards
not only amplitude parameters such as peak value and AUC,
but also the shape of the secretory response, which is more
delayed, especially for UPD15 subjects.
(Received 27 September 2012; returned for revision 21 October
2012; finally revised 10 December 2012; accepted 30 December
2012)
Introduction
Prader–Willi syndrome (PWS) is a complex disorder due to the
lack of expression of the paternally active genes in the PWS crit-
ical region on chromosome 15.1 In approximately 65–70% of
affected individuals, there is a deletion of the paternal chromo-
some (15q11-q13) (DEL15), whereas 30–35% of subjects have a
maternal uniparental disomy for chromosome 15 (UPD15).
PWS represents the most frequent cause of syndromic obesity,
occurring in 1 in 25 000 live births.2
The syndrome affects multiple body systems and its most con-
sistent characteristics include infantile hypotonia with feeding
problems, hyperphagia leading to severe obesity in early child-
hood, mental retardation, behavioural problems, dysmorphic
features, hypogonadism, and short stature.3 A typical pattern of
growth is described, with decreased linear growth velocity in
childhood and compromised final adult height. A complex
hypothalamic-pituitary dysfunction is currently thought to lie at
the root of PWS phenotype: it is a recognized cause of compul-
sive appetite and explains sleep-related breathing disorders, body
temperature instability, hypogonadism, and altered GH secre-
tion.4 Spontaneous GH secretion is reduced and GH peak dur-
ing pharmacological stimulation test is less than 10 lg/l in 70%
of children.5 Information regarding GH secretory pattern in
adult patients with PWS is beginning to emerge, indicating that
GH deficiency (GHD) may be present in a significant percentage
of subjects.6–8 In addition, we have recently demonstrated a dif-
ferent pattern of GH secretion among PWS subjects with differ-
ent genetic subtypes, higher GH responses being found in
DEL15 patients in comparison with those with UPD15.9 The
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aetiology of the impaired GH secretion in PWS, however,
remains controversial due to the high frequency of obesity. As
far as weight excess is concerned, obesity associated with PWS is
often massive and many subjects are more than twice their ideal
bodyweight. Obesity is known to be associated with a decreased
spontaneous GH release as well as with an impairment of stimu-
lated GH secretion.10 Thus, permanent GHD due to hypotha-
lamic-pituitary disease may be difficult to distinguish from the
reversible blunting of GH release in obese patients.
This background suggests the importance of analysing pitui-
tary responsiveness to standard GH stimulation tests. A first
issue is the need for an adequate sample size enabling the detec-
tion of significant differences between obese controls and sub-
populations of PWS subjects. Moreover, the literature on the
analysis of hormonal responsiveness to stimuli has shown that
the use of simple quantitative parameters as the peak value in
plasma and the plasma AUC is not sufficient to capture the full
complexity of glandular responses.11–13 Indeed, due to hormonal
clearance, the profile of hormone concentration in plasma pro-
vides only an indirect picture of the instantaneous secretion rate
by the pituitary. To make an example, a short secretion episode
would result in a sudden rise followed by a slower exponential
decay. Mathematically speaking, this distortion is described by
the convolution of the instantaneous secretion rate with the hor-
monal clearance function. To remove such distortion, one can
resort to the so-called deconvolution analysis that makes it pos-
sible to recover the instantaneous secretion rate of the pituitary.
In turn, this offers a precious insight into the timing of hor-
mone prediction. Along this line, in this retrospective work, a
deconvolution analysis of both PWS and obese GH responses is
performed, to define quantitative and qualitative aspects of the
pituitary response and to better understand the possible differ-
ences in terms of GH secretion response between PWS patients
and obese subjects.
Materials and methods
Patients
Sixty-five PWS patients, 24 males and 41 females, aged
18–412 years, consecutively recruited between July and December
2005 from Istituto Auxologico Italiano and Ospedale Pediatrico
Bambino Gesu, were included in the study (Table 1). All patients
showed the typical PWS clinical phenotype.3 Cytogenetic analysis
was performed in all subjects, and 49 of them had DEL15, while
UPD15 was found in the remaining 16 individuals. Standing
height was determined by a Harpenden Stadiometer (Holtain Ltd,
Dyfed, UK) and expressed as standard deviation score for height
(HSDS), according to the published Italian standards.14 In our
population, HSDS ranged from 063 to 564 (mean SD:
263  102). Body weight was measured to the nearest 01 kg,
by using standard equipment. BMI was defined as weight in kilo-
grams divided by the square of height in metres. Mean BMI was
419  112 (range: 200–708). At the time of the study, 17 of the
women were undergoing sex steroid substitution. Twenty-one
PWS subjects had previously undergone GH treatment,
withdrawn in all cases at least 2 years before starting the study
protocol.
As controls, we evaluated 17 patients (7 males, 10 females)
with essential obesity, matched for age, gender- and BMI
(Table 1). Their individual characteristics have been previously
described.7 As expected, HSDS of obese controls was signifi-
cantly higher than that observed in PWS patients. All PWS and
control obese subjects provided normal findings in main labora-
tory tests, including thyroid, liver and kidney function.
Endocrine protocol
All subjects underwent a standard GH Releasing Hormone
(GHRH)+arginine (ARG) test. Tests started at 8:30 am after
overnight fasting, with the patients recumbent. Fifteen minutes
after an indwelling catheter had been placed in an antecubital
vein, each subject received GHRH (1–29) injection (GHRH, Fer-
ring GmbH, Kiel, Germany; 1 lg/kg as i.v. bolus at 0 min).
From 0 to 30 min after GHRH administration, 05 g/kg (maxi-
mum dose 30 g) of ARG hydrochloride (SALF, Bergamo, Italy)
was infused. Blood samples for GH determination were drawn
at 15, 0, 30, 45, 60, 90 and 120 min after the i.v. bolus of
GHRH. No patient underwent caloric restrictions before the test
was performed.
Hormonal dosages were centralized in the laboratory of the
Istituto Auxologico Italiano. GH levels were measured by chem-
iluminescence (Immulite 2000 Analyser, DPC, Los Angeles, CA,
USA) calibrated against World Health Organization International
Table 1. Clinical and laboratory data of Prader-Willi (PWS) patients and obese controls
PWS DEL15 PWS UPD15 PWS (all) Obese controls
Number 49 16 65 17
Gender (M:F) 18:31 6:10 24:41 7:10
Age 260  59 261  74 260  62 280  58
BMI 412  118 441  94 419  112 434  44
HSDS 262  108 284  105 263  102 005  092*
IGF-I (lg/l) 1342  753 1169  547 1300  708 2069  1007†
Data are reported as mean  SD. DEL15, interstitial deletion of the proximal long arm of chromosome 15; UPD15, uniparental maternal disomy for
chromosome 15; BMI, body mass index (kg/m2); HSDS = Height Standard Deviation Score. *P < 00001 vs PWS DEL15, PWS UPD15 and all PWS;
P < 00001 vs all PWS; †P < 0005 vs PWS DEL15 and PWS UPD15.
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Reference Preparation (WHO 1st IRP) 80/505, having a sensitivity
of 001 lg/l and intra- and interassay coefficients of variation
(CVs) of 29–42% and 42–65% respectively. All measurements
were performed in a single run.
Serum IGF-I concentrations were determined by chemilumi-
nescence IGF-I immunoassay by Liaison (Nichols Advantage,
San Juan Capistrano, CA, USA), with intra- and interassay CVs
of 48% and 67% respectively. All samples were measured in
the same batch.
The entire study protocol was approved by the ad hoc Ethical
Committee of Istituto Auxologico Italiano. Written informed
consent was obtained from patients, or from their parents when
necessary.
Response assessment
Peak value. The gland response to the stimulus can be easily
assessed through the evaluation of the highest plasma
concentration, i.e. the response peak value, among the meas-
urements following GHRH+ARG stimulation. However, the true
peak value of the concentration profile might not be coincident
with the highest collected sample. Furthermore, the peak value is
rather sensitive to the measurement noise, because such a value is
based only on a single sample.
Standard AUC. A more reliable assessment of the global effect
of the stimulus is usually obtained by computing the AUC of
the plasma concentration samples through the trapezoidal rule.
The AUC should be calculated from the instant when the
stimulus is given to the time when its effect ceased. However,
spontaneous secretions may occur before and/or after the
stimulation. In particular, standard AUC may be affected by
several artefacts: spontaneous prestimulus secretion may
interfere with the AUC of interest, the stimulation effect may
last beyond the last observed sample and a poststimulus
secretion episode may interfere with the GH response to the
stimulus.
AUC of the ISR. A way to prevent possible artefacts is to assess
gland responsiveness through the evaluation of the AUC of the
Instantaneous Secretion Rate (ISR) signal. The glandular ISR
cannot be directly measured. However, the GH plasma
concentration, the glandular ISR and the clearance are linked by
a convolution integral that can be leveraged to reconstruct the
ISR profile by so-called deconvolution analysis.11,15 Previous
works showed that the AUC of the ISR can be assessed by a
linear combination of plasma hormone concentration
samples.13,16 By applying this method to our sampling schedule,
the following formula is obtained:
AUC ISR ¼ 0:2537y1 þ 1:9011y2 þ 0:6998y3
þ 1:9032y4 þ 2:5714y5 þ 2:0189y6
ð1Þ
where yi, i = 1,…, 6, are the serum GH concentration observa-
tions at the sampling times t = 0, 30, 45, 60, 90, 120. This
approach should reduce the artefacts due to possible spontaneous
secretion events. Moreover, this technique is less sensitive to mea-
surement errors compared with the evaluation of the peak value
alone.
AUC due to the stimulus. According to the usual linear model of
GH kinetics, the GH concentration profile is given by the
superposition of the response to the GHRH+ARG stimulus and
possible pre- and post-stimulus spontaneous secretion.
Accordingly, the AUC of the plasma GH can be seen as the sum
of a term AUCGH due to the GHRH+ARG stimulus and other
terms due to spontaneous secretion. Note that AUCGH and
AUCISR are linked through the fractional hormone clearance
(FCR):
AUC GH ¼ AUC ISR
FCR
ð2Þ
The FCR can be regarded as the inverse of the AUC of the
plasma concentration g(t) obtained through a unitary-per-vol-
ume hormone bolus. For GH, g(t) is usually approximated by
an exponential function, that is
gðtÞ ¼ eat t 0 ð3Þ
where FCR = a = 0077911 is the population value of FCR.
Hence, by means of equations (1) and (2),
AUCGH ¼3:2567y1 þ 24:4044y2 þ 8:9833y3
þ 24:4313y4 þ 33:008986y5 þ 25:9166y6
ð4Þ
where the coefficients are just obtained by dividing the weights
in equation (1) by the FCR.
Secretion response analysis
To evaluate the shape of the GH secretion response, a Secre-
tion Response Analysis (SCR) was introduced. Given the ISR
profile of a subject (Fig. 1, upper panel), the normalized unit-
area ISR curve is obtained (Fig. 1, middle panel), so as to make
the response profiles comparable among different subjects.
From that, the Cumulative Secretion Rate (CSR) (Fig. 1, lower
panel) can be obtained. The half-secretion time is defined as
the time when the CSR curve reaches 05, corresponding to
50% of secretion. The half-secretion time measures the response
delay. In particular, slower responses yield longer half-secretion
times.
Results
In our study, the peak values of the GH response, the AUC due
to the stimulus of GHRH+ARG and the half-secretion times
were considered, see Table 2.
The differences in terms of peak values, AUCGH and half-
secretion times were evaluated by means of the t-test (see
Table 2). Concerning peak values and AUCGH, the differences
were statistically significant (P-value <005) between PWS
DEL15 and PWS UPD15, as well as between PWS UPD15 and
© 2013 John Wiley & Sons Ltd
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obese controls, also when the populations were stratified with
respect to the gender, the only exception being the comparison
of AUCGH between UPD15 males and obese males that was not
significant (data not shown).
Furthermore, considering half-secretion times, statistically sig-
nificant differences were observed between the whole popula-
tions of PWS adults and obese controls (P-value: 00012), as
well as between the same female populations (P-value: 00042).
Moreover, significant P-values were obtained for female subjects
when PWS adults were stratified by karyotype and compared
with obese controls (P-values: 0018 and 0005, when consider-
ing UPD15 and DEL15 populations, respectively).
IGF-I levels were significantly higher in the obese controls
when compared with all PWS as well as to the different genetic
subtypes of PWS (Table 1). By means of deconvolution analy-
sis,12 the instantaneous secretion rate profiles of all the subjects
of the two populations were reconstructed. Figure 2 shows an
example of the deconvolution and reconvolution profiles of a
subset of subjects. In accordance with Table 2, it can be seen
that obese controls have a higher GH response than PWS adults
(Fig. 2).
The response delay was assessed through the comparison of
the half-secretion time of the subpopulations. Figure 3 shows
the mean cumulative secretion rates of each subpopulation. In
particular, obese controls have the lowest half-secretion time,
whereas the PWS UPD15 have the most delayed response,
probably due to the higher severity of the syndrome. In gen-
eral, PWS subjects show a more delayed response than the
obese control subjects. However, PWS DEL15 have a slightly
faster GH response compared with PWS UPD15 adults
(Fig. 3).
Concerning BMI, no statistically significant differences were
found between PWS adults (considering both the whole popula-
tion and the two karyotypes) and obese controls, also when
stratifying subjects by gender. The possible correlation between
AUCGH and the available covariates, i.e. age, BMI, HSDS and
IGF-I, was evaluated for each subpopulation. Furthermore,
PWS subjects were stratified by karyotype. Figure 4 shows that
AUCGH is negatively correlated with BMI in the entire group of
PWS adults (correlation coefficient: 0584, P-value: <001%) as
well as in PWS DEL15 (correlation coefficient: 0626, P-value:
<001%). Concerning the obese controls, AUCGH is positively
correlated with IGF-I (correlation coefficient: 0579, P-value:
0015) (Fig. 4).
Discussion
The aetiology of impaired GH secretory pattern in PWS is still
controversial, because the cause of reduced GH levels may be
attributed to the effect of obesity alone. However, the clinical
picture of PWS in adulthood strongly supports the presence of
GHD. Apart from short stature, both PWS and GHD are char-
acterized by impaired physical strength. Decreased left ventricle
mass and lower chronotropic response to an adrenergic stimulus
have been demonstrated.17 Furthermore, adults with PWS
showed both a reduced bone mineral density and an abnormal
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Fig. 1 Secretion Response Analysis (SRA) of two subjects with different
karyotypes (Subject A with DEL15 and Subject B with UPD15). The
ISR profiles of the two subjects are shown in the upper panel. These
curves are then normalized to have unit area (middle panel), to make
them comparable. The Cumulative Secretion Rate (CSR) plot is
performed to assess the half-secretion times of the two subjects. Subject
A has a shorter half-secretion time (hst1), that is the response of
subject B is more delayed than that of subject A.
Table 2. Population statistics (mean  SD) of PWS adults, stratified by
karyotype, and obese controls
Population Peak value (lg/l) AUCGH (lg/l/h)
Half-secretion
time (min)
Obese controls 157  120 9664  7508 393  132
PWS (all) 101  113 7440  9501 524  126**
PWS DEL15 119  121† 8792  10386† 517  123*
PWS UPD15 48  64* 3298  3966* 545  136*
*P-value <1% between obese control adults and PWS subjects;
**P-value <01% between obese control adults and PWS subjects;
†P-value <1% between PWS adults with different karyotype).
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body composition, with increased fat to lean mass ratio and
decreased lean body mass.18 In this context, it has been found
that stimulated GH levels are different in PWS adults when
compared with patients with similar BMI7 as well as with obese
subjects having similar fat mass percentage.19 In addition,
reduced GH stimulated levels are present in a significant propor-
tion of PWS adults.6–8 Nevertheless, all previous studies have
adopted a quantitative assessment of gland responsiveness to
exogenous stimuli, using the peak value of the hormone concen-
trations in plasma, or the AUC. However, none of these meth-
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ods is satisfactory, due to either sensitivity to measurement
errors or various sources of bias.
This is the first study to provide a thorough investigation of
the impairment of GH secretory response in PWS subjects. In
particular, both the quantitative and qualitative features of
responses to GH stimuli have been investigated.
In its basic version, the study of pituitary responsiveness may
rely on the quantitative assessment of few phenomenological
parameters, such as the peak value of the GH concentration and
the area under its curve (AUC). However, as shown in previous
studies,11–13,16 a better description of the characteristics of the
glandular secretory response is obtained by taking into account
that plasma GH concentration provides just an incomplete and
indirect picture of pituitary responsiveness: incomplete because
only few blood samples are collected at prespecified instants in
time and indirect because we do not have direct access to the
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glandular secretion rate. Indeed, the plasma concentration of
GH is the convolution of the Instantaneous Secretion Rate (ISR)
with the hormone clearance function, meaning that deconvolu-
tion analysis is needed to recover the ISR, which best reflects the
quantitative and qualitative aspects of pituitary response.11
The use of deconvolution analysis has been shown to over-
come several limitations of clinical responsiveness studies char-
acterized by sparse and limited sampling. In particular, rather
than relying on a single peak value that is rather sensitive to
measurement errors, the quantitative response can be measured
by the AUC of the ISR.13,16 In fact, such a secretory AUC is less
prone to biases due to the short duration of the sampling
schedule that rarely exceeds few hours.
By using deconvolution methodology previously developed
and validated on a variety of pituitary hormones,11,13,15 in the
present study, the responsiveness of PWS subjects has been char-
acterized. First of all, the quantitative impairment compared
with obese group was quantified. In this respect, it turned out
that the secretory response of PWS UPD15 subjects, measured
through both the peak value of the plasma GH concentration
and AUC of the ISR, was significantly lower than that of both
essential obese controls and PWS DEL15 subjects. For peak val-
ues, but not for AUC, the finding was maintained also if com-
parisons were performed between gender-matched groups. It is
noteworthy that statistically significant differences were not
found between PWS DEL15 and obese controls, thus highlight-
ing that, as far as GH impairment is concerned, the karyotype
identifies two distinct subpopulations of PWS subjects, accord-
ingly to our previous findings.9
A second relevant aspect is the qualitative secretion response
analysis of the pattern of GH secretion. This analysis was per-
formed by using a new parameter (the half-secretion time), rep-
resenting the time needed to deliver half of the total hormone
secretory response. To enable comparison, the ISR is normalized
to obtain a unit-area curve from which the Cumulative Secre-
tion Rate and the half-secretion time are obtained. In particular,
the longer the half-secretion time, the more delayed the gland
response.
A significant difference between the half-secretion time of
obese control subjects and the whole set of PWS adults was
observed, significance being maintained if the comparisons were
performed between PWS DEL15 and obese control subjects or
between PWS UPD15 and obese control subjects.
It is noteworthy that the PWS DEL15 subpopulation, which
is not significantly different from obese controls in terms of
response amplitude (either peak value of GH response or
AUC), is conversely significantly different in terms of response
pattern, as characterized by the half-secretion time. In view of
these findings, it can be conjectured that the common trait
shared by the two subpopulations of PWS subjects is more
related to the pattern of secretory profiles rather than the mere
amplitude.
The delayed GH response in all PWS subjects, compared with
obese controls, is suggestive of an impairment of GH hypotha-
lamic regulation network, involving the interplay of both GHRH
and somatostatin tone. Concerning this issue, hypothalamic
anomalies are well proven in PWS,20,21 consistent with deficiency
of many pituitary hormones22,23 and brain imaging24 and histo-
logical abnormalities.25 The presence of a GH/IGF-I axis impair-
ment in PWS seems to be supported by our data of lower IGF-I
levels in respect of obese controls.
One limitation of this study includes the lack of a control
group of normal-weight adults. In fact, knowing how much and
in which way the obese group differed from the normal BMI
population would render the study more complete. Further
research is needed to better discriminate the impact of fat mass
on the pattern of GH secretion.
In conclusion, this study demonstrates that quantitative and
qualitative analyses complement each other to provide a compre-
hensive description of GH responsiveness, highlighting the key
differences between PWS adults and obese controls, which would
not be fully characterized by a purely quantitative analysis. More-
over, our results support the view that the degree of GH impair-
ment in PWS depends on the genetic subtypes, with a lower GH
secretion ability in the PWS UPD15 subjects in respect of PWS
DEL15 patients.
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